Drugs / YOLT-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06082050 | Nov 2023 → Jul 2025 overdue | amyloidosis | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06539208 | May 2024 → Jun 2025 overdue | familial amyloid neuropathy | YolTech Therapeutics Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YOLT-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06539208 ↗ |
| Route | Intravenous | “Intravenous YOLT-201” NCT06082050 ↗ |